Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
52W High
$230.02
52W Low
$91.86
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.47
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
16.00
EV/EBITDA (<8 favorable)
20.20
EV/Revenue (<3 favorable)
2.65
P/S (TTM) (<3 favorable)
2.00
P/B (<3 favorable)
2.41
Ownership
Institution‑heavySource: Overview
Insiders (1–5% typical)
1.00%
Institutions (25–75% balanced)
105.66%
Shares Outstanding
49,214,200
Float
48,623,100
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
4,028,615,000
Gross Profit (TTM)
1,411,084,000
EPS (TTM)
-1.30
Profit Margin (>10% good)
-0.02%
Operating Margin (TTM) (higher better)
0.17%
ROE (TTM) (>15% strong)
-0.02%
EPS YoY (Quarterly) (>10% good)
-0.39
Revenue YoY (Quarterly) (>8% good)
0.01
Momentum
Bearish momentumValue
0.6669
Previous
1.2649
Trend
Falling
Signal Cross
No cross
As of
Sep. 09, 2025